natgillin/translations-raw huggingface dataset:
and R22 are each independently selected from hydrogen, C1-6alkyl, C3-7cycloalkyl, C1-6alkylcarbonyl and arylC1-6alkylcarbonyl, any of said groups being optionally and independently substituted with one or more, preferably one or two, substituents selected from halo, hydroxy, amino, mono- or di(C1-6alkyl)amino, C1-6alkyl, polyhaloC1-6alkyl, C1-6alkyloxy, aryl and heteroaryl; 
Cagcikloalkilkarboniloksi, arilkarboniloksi ili heteroarilkarboniloksi, svaka od navedenih skupina je proizvoljno i nezavisno supstituirana sa jednim ili više, poželjno jednim ili dva, supstituenta odabrana od halo, hidroksi, cijano, nitro, karboksila, amino, mono- ili di(C, salkiljamino, Ci .salkila, polihaloC, salkila, arila, heteroarila, C,.galkiloksi, C,_galkilkarbonila, C, salkiloksikarbonila 1 Ci.galkilkarboniloksi; te
Alternatively, a compound of formula 3 may be reacted with a C1-C6alkyl halide. 
Alternativno, spoj formule 3 može reagirati sa Cj-CÂ«-alkil halogenidom.
reacting a compound of Formula A in an organic solvent with base and (S)-propylene glycol, optionally adding seeds of the (S)-PG compound Ia, to yield the compound of Formula Ia. 
reakcije spoja sa Formulom A u organskom otapalu sa bazom i (S)-propilen glikolom, te proizvoljno dodavanje zametaka (S)-PG spoja Ia, da se dobije spoj sa Formulom Ia.
A composition comprising a zinc ester functional polymer and particles of copper pyrithione, which are obtained by reacting an acid functional polymer with zinc pyrithione and a copper compound selected from the group consisting of copper salts, copper carboxylates, copper hydroxide, elemental copper and combinations thereof, wherein said particles have an average aspect ratio within a range of from about 8 to about 15, preferably from about 9 to about 12. 
Sastav, koji obuhvaća funkcionalni polimer estera cinka 1 dijeliće bakar-piritiona, koji se dobije spajanjem kiselo-funkcionalnog polimera sa cink-piritionom i jednog spoja bakra odabranog iz skupine koja se sastoji iz soli bakra, karboksilata bakra, hidroksida bakra, elementarnog bakra i njihovih kombinacija, naznačen time da dijelići imaju prosječni stranični odnos unutar područja od oko 8 do oko 15, u prednosti su od oko 9 do oko 12.
The present invention relates to compounds of formula I: 
PATENTNI ZAHTJEVI nm Pe Spoj s formulom I:
The method of claim 1, wherein a minimum size of the quantization unit is adjusted per picture. 
2. - Postupak prema zahtjevu 1, gdje se minimalna veličina jedinice kvantizacije podešava prema slici.
A compound according to claim 17, or a pharmaceutically acceptable salt thereof, wherein R5 is 2-hydroxyethyl, 2-hydroxy-1-methylethyl, 2,3-dihydroxypropyl or 2-hydroxy,-1-hydroxymethylethyl. 
Spoj u skladu s patentnim zahtjevom 17, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R5 je 2-hidroksietil, 2-hidroksi-1-metiletil, 2,3-dihidroksipropil ili 2-hidroksi,-1-hidroksimetiletil.
To this end, the sign of each non-zero coefficient in the list E1 is entropically encoded. If the number of modifiable coefficients is greater than the threshold TSIG, then during a step C 8 represented in FIG. 
- broj koeficijenata, od prvog nenultog koeficijenta do zadnjeg nenultog koeficijenta, uključujući prvi i zadnji nenulti koeficijent, je veći od četiri;
FIG. 10 shows a DSC spectrum of the co-crystal of VX-950 and 4-hydroxybenzoic acid as an acetonitrile solvate. 
Bac i 4-hidroksibenzojeve kiseline iznosi otprilike 1:1, to gdje sukristal ima signal u svom DSC tcrmogramu na otprilike 10
Figure 4 schematically represents a workpiece consisting of two pipes 12 and 13 made of stainless steel with a diameter of 40 mm which are welded together at right angles. 
Slika 4 shematski prikazuje komad koji se treba obraditi i koji se sastoji od dvije cijevi 12 i 13 koje su načinjene od nehrđajućeg čelika, s promjerom od 40 mm i koje su zavarene zajedno pod pravim kutom.
is C1-C6 alkyl (optionally substituted with 1, 2 or 3 fluorine atoms) or C3-C6 cycloalkyl wherein one C-C bond within the cycloalkyl moiety is optionally substituted by an O-C bond; 
R' je Cr-Cg alkil (izborno supstituiran s 1, 2 ili 3 atoma fluora) ili Ca-Cg cikloalkil, gdje jedna veza C-C u cikloalkilnom ostatku je izborno zamijenjena vezom O-C;
Then, the material was loaded with the material resulting from step (a). 
Tada, materijal je bio nanesen skupa s materijalom koji je dobiven u koraku (a).
the subject taking an effective amount of a second colon cleansing solution, the first colon cleansing solution being a solution comprising 
- primjena na subjektu djelotvorne količine druge otopine za čišćenje debelog crijeva, druga otopina za čišćenje debelog crijeva je otopina u skladu s patentnim zahtjevom 15.
A compound according to claim 1 wherein each R1 is independently selected from the group consisting of H, and halogen. 
Spoj prema zahtjevu 1 ili 2 naznačen time da R, je odabran iz skupine koja sadrži H, halogen.
A closure capsule for closing a container, comprising: 
PATENTNI ZAHTJEVI Kapsula za zatvaranje za zatvaranje posude, koja sadrži:
represents a hydrogen atom; 
predstavlja vodikov atom;
A pharmaceutical composition according to any one of claims 1-28, wherein such single dose form comprises an extended release formulation adapted for oral administration. 
Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-31, naznačena time što takav pojedinačni dozni oblik sadrži formulaciju sa produženim oslobađanjem prilagođenu za oralnu primjenu.
wherein t and Z are defined as in claim 1; alkyloxy substituted with a radical of formula 
\_f pri čemu su t i Z kako je definirano u patentnom zahtjevu 1; alkiloksi supstituiran sa radikalom formule KCteh
The monoclonal antibody of claim 9 for use in improving outcomes in orthopedic procedures, dental procedures, implant surgery, joint replacement, bone grafting, bone cosmetic surgery or bone repair such as fracture healing, nonunion healing, delayed union healing or facial reconstruction. A pharmaceutical composition comprising an antibody of any one of the preceding claims, and a pharmaceutically or physiologically acceptable carrier, excipient or diluent. 
Monoklonsko protutijelo prema bilo kojem od patentnih zahtjeva 10 do 17, naznačeno time, da se koristi u postupku poboljšanja ishoda kod ortopedskih zahvata, dentalnih zahvata, operacija usadka, zamjene zgloba, presađivanja kosti, kozmetičke operacije kosti i reparacije poput liječenja lomova, zacjeljivanja bez srastanja, zakašnjelog zacjeljivanja bez srastanja ili rekonstrukcije lica.
where a filter is made online and hereby opened for inflow and a filter is made offline and hereby closed for inflow by opening and closing, respectively, system valves upstream and downstream of the filter; 
– gdje se filtar uključi i tako otvori za dotok, a zatim se filtar isključi i tako zatvori za dotok otvaranjem odnosnom zatvaranjem sustavnih ventila uzvodno i nizvodno od filtra;
The method of claims 1 through 6 further comprising the step of axially injecting plasma into the FRC from the axially mounted plasma guns. 
Postupak prema zahtjevima od 1 do 6, naznačen time, da nadalje obuhvaća fazu aksijalnog injektiranja plazme u FRC iz aksijalno montiranih plazma pištolja.
In this context, the polymer may in particular be selected in the group consisting of shellac such as SSB® Aquagold, anionic copolymers based on methyl acrylate, methyl methacrylate and methacrylic acid such as Eudragit® FS30D, methacrylic acid and methyl methacrylate copolymers (1:2 ratio) such as Eudragit®S-100 and Eudragit® S12,5, HPMCAS such as Aqoat® AS-MF, MG or HF grades or hydroxypropyl methylcellulose phthalate (HPMCP) such as HP-55 grade. 
Formulacija u skladu s patentnim zahtjevom 5 ili 6, pri čemu se polimer otapa kod pH jednakog 6.0 ili višeg, posebno kada je pH-ovisni polimer odabran iz grupe koja se sastoji od - < shellaca hidroksipropilmetilceluloza acetat sukcinata hidroksipropilmetilceluloza ftalata anionskih kopolimera na temelju metil akrilata, metil metakrilata i metakrilne kiseline, 1 kopolimera metakrilne kiseline i metil metakrilata (u omjeru 1:2).
The compound, or a single stereoisomer, racemate, mixture of enantiomers and diastereomers, or geometric isomer thereof, of Claim 9, where the cancer is breast cancer, colon cancer, rectal cancer, endometrial cancer, gastric carcinoma, glioblastoma, hepatocellular carcinoma, small cell lung cancer, non-small cell lung cancer, melanoma, ovarian cancer, cervical cancer, pancreatic cancer, prostate carcinoma, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), or thyroid carcinoma. 
Spoj ili njegov tautomer, pojedinačni stereoizomer, racemat, smjesa enantiomera i diastereomera, ili geometrijski izomer, prema patentnom zahtjevu 8, gdje je kancer – kancer dojke, kancer debelog crijeva, rektalni kancer, endometrijalni kaner, karcinom želudca, glioblastom, hepatostanični karcinom, sitnostanični kancer pluća, nesitnostanični kancer pluća, melanom, kancer jajnika, cervikalni kancer, kancer pankreasa, karcinom prostate, akutna mijelogena leukemija (AML), kronična mijelogena leukemija (CML), ili karcinom tireoidee.
Use of a conjugate according to claim 1 or 2, for the manufacture of a medicament for carrying drugs across a blood-tissue barrier. 
Uporaba konjugata u skladu s patentnim zahtjevom 1 ili 2, za proizvodnju medikamenta za prijenos lijekova kroz krvno-tkivnu barijeru.
There are muscarinic receptors on peripheral systems such as salivary glands and gut and therefore the use of systemically active muscarinic receptor antagonists is limited by side-effects such as dry mouth and constipation. Thus the bronchodilatory and other beneficial actions of muscarinic receptor antagonists are ideally produced by an inhaled agent which has a high therapeutic index for activity in the lung compared with the peripheral compartment. 
Muskarinski receptori postoje na perifernim sustavima, kao što su žlijezde slinovnice i probavni trakt i stoga je uporaba antagonista muskarinskih receptora sa sistemskim učinkom ograničena nuspojavama, kao što su suha usta i zatvor, Prema tome, bronhodilatorno i drugo blagotvorno djelovanje antagonista muskarinskih receptora se idealno proizvodi inhaliranim agensom koji ima visoki terapeutski indeks za djelovanje u plućima, u usporedbi s učinkom na periferno tkivo,
After the transfer has been completed allow the formulated mass initially transferred to rest for 20 minutes. 
Nakon što je prijenos završen ostaviti formuliranu masu koja je na početku prenijeta da odstoji 20 minuta.
With continued reference to the heat transport system of the preceding two paragraphs, in certain embodiments the heat transport system may include at least one thermoelectric heat pump arranged to receive heat from the fluid conduit and transport heat to the reject heat exchanger, wherein the at least one thermoelectric heat pump is operated responsive to temperature of the chamber or surface. 
Sustav prijenosa topline prema zahtjevu 4, naznačen time, da sustav prijenosa topline obuhvaća najmanje jednu termoelektričnu toplinsku pumpu namještenu za primanje topline iz fluidnog cjevovoda i za prijenos topline do povratnog izmjenjivača topline, te time, da najmanje jedna termoelektrična toplinska pumpa radi u skladu s reakcijom na temperaturnu vrijednost u komori ili na površini.
A compound of general formula (I) according to anyone of the claims from 1 to 2 wherein Y is a bivalent radical having the following meaning: straight or branched C2-C6 alkylene being substituted with -ONO2 or T, wherein T is as defined in claim 1; 
Spoj opće formule (I) prema bilo kojem od patentnih zahtjeva 1 do 2, naznačen time da Y jest dvovalentni radikal koji ima sljedeće značanje: a) - ravni ili razgranati C,-C4 alkilen koji može biti supstituiran s -ONO, ili T, gdje T jest kao što je definirano u patentnom zahtjevu 1,
the separated zofenopril calcium is purified by washing with water or methanol; and/or 
(ix) razdvojeni zofenopril kalcij je pročišćen ispiranjem vodom ili metanolom; i/ili
Method according to any one of claims 1-6, wherein one or more processing aids such as hop products containing a - and B - acids from hops, are added in any of steps (1) and (2). 
Postupak prema bilo kojem od zahtjeva 1-6, naznačen time da se jedno ili više sredstava za olakšavanje obrade, kao što su proizvodi hmelja koji sadrže a - kiseline i B - kiseline iz hmelja, dodaju u bilo kojem od koraka (1) i (2).
and tautomers and pharmaceutically acceptable salts thereof, and polymorphic forms thereof, with the proviso that when the linker (L) is - CH2-S- then HET-1 is neither imidazo[1,2-a]pyridine nor imidazo[1,2-a]pyrimidine. 
te njegovi tautomeri i farmaceutski prihvatljive soli, i njihovi polimorfni oblici, uz uvjet da kada linker (L) je -CH2-S- tada HET-1 nije niti imidazo[1,2-a]piridin niti imidazo[1,2-a]pirimidin.
To this solution was added maleic acid (82.5 g) and the resulting precipitate was collected, washed with industrial methylated spirit and dried at 55° to give the title compound (304 g) as a white solid, again confirmed spectroscopically to be the desired product. 
U ovu otopinu se doda maleinska kiselina (82,5 g) i dobiveni talog se sakuplja, pere industrijskim metiliranim alkoholom i suši na 55" da bi se dobio naslovni spoj (304 g) kao bijela čvrsta supstanca, ponovno spektroskopski potvrđeno da je željeni proizvod.
The pharmaceutical composition of claim 12, wherein in Formula (I'), R1 is a hydrogen atom, and R2 is a hydrogen atom; a hydroxy group; a straight or branched C1-C6 alkyl group; a straight or branched C1-C5 alkoxy group; or a straight or branched C1-C3 thioalkyl group. 
Spoj formule (I) iz patentnog zahtjeva 12 za njegovu primjenu prema patentnom zahtjevu 12, gdje u formuli (I), R' je atom vodika, i R* je atom vodika; hidroksi grupa; ravna ili razgranata C,-C4 alkil grupa; ravna ili razgranata Ci-Cs alkoksi grupa; ili ravna ili razgranata C,-C3 tioalkil grupa.
The receiver of paragraph 13, wherein the L1 signaling information has data slice ID information that identifies the data slice. 
Prijamnik iz patentnog zahtjeva 13, pri čemu informacija signaliziranja L1 ima ID informaciju podatkovnog Teza koja identificira podatkovni rez.
The fuel gas, the methane number of which is adjusted, is supplied to the heater 47 through the sub LNG supply line L24, is further heated to a temperature required in the sub engine, and is then supplied as fuel to the sub engine. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 4, naznačen time što pomoćna linija za slanje LNG (L24) dodatno sadrži grijač (47), podešen za podešavanje temperature goriva, čiji se metanski broj podešava u separatoru plina od tekućine do vrijednosti potrebne za pomoćni motor.
A peptide consisting of the amino acid sequence according to SEQ ID No. 6 for use in the treatment of cancer. 
Terapijski učinkovita količina farmaceutskog sastava iz bilo kojeg od prethodnih zahtjeva za uporabu u liječenju ili sprječavanju karcinoma kod pacijenata,
Use of a compound according to claims 1 to 4 for the preparation of a medicament for preventive and/or therapeutic treatment of non-insulin dependent diabetes; obesity; manic depressive illness; schizophrenia; alopecia; or cancers. 
Upotreba spoja prema patentnim zahtjevima 1 do 4, naznačena time što je navedeni spoj namijenjen pripravi lijeka za sprječavanje i/ili terapijsko liječenje dijabetesa neovisnog o inzulinu; pretilosti; manično-depresivne bolesti; shizofrenije; alopecije; ili raka.
The compound or composition for use according to claim 1, wherein the disease or disorder is fallopian tube cancer. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je rak dojke.
an IL-17RA/IL-17RC complex and IL12RB1. The IL-17 antagonist of Claim 1, wherein the bispecific antibody that binds to and inhibits the activity ofIL-17 and IL-23; IL-17 and IL-23p19; IL17RA and IL-23; or IL-17RA and IL-23p19. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 1, naznačen time, da IL-17 antagonist je bispecifično antitijelo ili fragment bispecifičnog antitijela koje se veže na i inhibira djelovanje a) IL-17 i IL-23p19, ili b) IL-17 i IL-23R.
aryl is phenyl, biphenyl or naphthyl, and heterocycle is a 4 to 7 membered monocyclic ring having 1, 2, 3 or 4 heteroatoms selected from nitrogen, oxygen and sulfur, and provided that when R3 is hydroxyl, alkyl, then R1, is halogen, aryl,; and further provided that when R3 is aryl, then R7 is not hydrogen, and further provided that 2-acetyl-7-chloro-naphtho[2,3-b]furan-4,9-dione and 2-acetyl-7-fluoro-naphtho[2,3-b]furan-4,9-dione are excluded; and 
gdje svaki alkil sadrži 1 do 6 atoma ugljika, alkenil sadrži 2 do 12 atoma ugljika i barem jednu dvostruku vezu ugljik-ugljik, alkinil sadrži 2 do 12 atoma ugljika i barem jednu trostruku vezu ugljik-ugljik, cikloalkil sadrži 3 do 8 atoma ugljika, cikloalkenil sadrži 3 do 8 atoma ugljika, aril je fenil, bifenil ili naftil, i heterocikl je 4 do 7-eročlani monociklički prsten s 1, 2, 3 ili 4 heteroatoma izabrana između dušika, kisika i sumpora, i uz uvjet ako je R3 hidroksil, alkil, onda je R1 halogen, aril; i dalje uz uvjet ako je R3 aril, onda R7 nije vodik, i dalje uz uvjet da su isključeni 2-acetil-7-kloro-nafto[2,3-b]furan-4,9-dion i 2-acetil-7-fluoro-nafto[2,3-b]furan-4,9-dion; i
The benzoylpyrazole compound or its salt according to claim 2, wherein R1 is methyl, R2 is a hydrogen atom, R3 is ethyl, R4 is methyl, R5 is methoxymethyl, R6 is methylsulfonyl, and A is represented by the formula (a-1): 
Spoj benzoilpirazola ili njegove soli u skladu s patentnim zahtjevom 2, naznačen time, da je R! metil, R? je atom vodika, R? je etil, R* je metil, R* je metoksimetil, R" je metilsulfonil a A je predstavljen formulom (a-1):
The method according to any of the proceedings claims 1-5, wherein the application, and associated data needs are stored in the database system, comprising one or more of the following fields: name of applications, protocol type, Bandwidth, IP-Packets lost, latency of transmission, QoS (Quality of Service), QoE (Quality of Experience), received signal strength and direction, connected cell and contextual usage information. 
Postupak sukladno bilo kojem od prethodnih zahtjeva 1- 4, pri čemu aplikacija, i povezane potrebe za podacima su pohranjene u sustavu baze podataka, obuhvaćaju jedno ili više sljedećih polja-: naziv aplikacija, vrstu protokola, širokopojasnost, IP-Pakete koji su izgubljeni, latenciju prijenosa, kvalitetu usluge, kvalitetu iskustva, snagu i usmjerenje primljenog signala, spojene stanice i kontekstualnu uporabu informacija.
The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein A represents a phenylene group, a thienylene group, a pyrazolylene group or a pyridylene group; and E represents an azetidine ring, a pyrrolidine ring, a piperidine ring or a piperazine ring or wherein A represents a phenylene group; and E represents an azetidine ring or a piperidine ring or wherein A represents a phenylene group; and E represents a piperidine ring. 
Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1 ili 2, naznačen time da A predstavlja skupinu fenilen, skupinu tienilen skupinu, skupinu pirazolilen ili skupinu piridilen; i E predstavlja azetidinski prsten, pirolidinski prsten, piperidinski prsten ili piperazinski prsten ili pri čemu A predstavlja skupinu fenilen; i E predstavlja azetidinski prsten ili piperidinski prsten ili pri čemu A predstavlja skupinu fenilen; i E predstavlja piperidinski prsten.
a tubular body (1) formed by metal material having two open ends, 
(1) tijelo cjevastog oblika (1) s dva otvorena završetka,
The cell of claim 1, further comprising a signal peptide sequence which precedes the at least one recombinant nucleic acid sequence encoding the phagolysosomal escape peptide or polypeptide. 
Stanica Mycobacterium, naznačena time što je oskudna ureazom i obuhvaća najmanje jednu rekombinantnu molekulu nukleinske kiseline koja kodira peptid ili polipeptid za bijeg iz fagolizosoma.
DETAILED DESCRIPTION OF A PREFERRED EMBODIMENTS 
Detaljan opis poželjnih utjelovljenja
For example, the fourth dosage form may comprise, for example, 10, 20, 30, or 40 mg of buprenorphine for a dosing period of 7 days. 
Na primjer, četvrta doza može sadržavati, na primjer, 10, 20, 30 ili 40 mg buprenorfina u periodu doziranja od sedam dana.
which is coupled with Compound F of the formula to afford Compound G of the formula, which is optionally crystallized to improve quality, and 
Spoj F da se dobije Spoj G formule, koji po izboru može kristalizirati radi poboljšanja kvalitete, 1 H -N S
The solid pharmaceutical composition of clause 1, further comprising an excipient selected from the group consisting of mannitol, xylitol, sorbitol, maltol, maltitol, lactose, sucrose, maltose, cyclodextrin, and combinations thereof. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 1, koja nadalje sadrži ekscipijens koji se bira iz skupine koju čine manitol, ksilitol, sorbitol, maltol, maltitol, laktoza, saharoza, maltoza, ciklodekstrin, i njihove kombinacije.
The process according to claim 19, wherein the dispersing agent is added prior to the concentrating step. 
Postupak prema zahtjevu 13, naznačen time što se disperzno sredstvo dodaje prije koraka koncentriranja.
The formulation according to any one of claims 1 to 12 for use in treating a disease or disorder of a mammal associated with reduced endogenous testosterone production, wherein the formulation is transdermally administered to a skin or mucosal membrane of said mammal and wherein said mammal is preferably a male mammal. 
Formulacija prema bilo kojem od zahtjeva 1 do 12, naznačena time, da se upotrebljava za tretman bolesti ili poremećaja kod sisavca, pri čemu je navedena bolest/poremećaj povezana sa smanjenom endogenom proizvodnjom testosterona, pri čemu se navedena formulacija primjenjuje transdermalno na kožu ili sluznicu navedenog sisavca i pri čemu je navedeni sisavac poželjno sisavac muškog spola.
Pharmaceutical composition according to any one of claims 1, 4, 5 or 6, wherein the inflammatory pulmonary disease is selected from the group consisting of asthma, COPD, sclerosis, alveolitis, sarcoidosis, idiopathic pulmonary fibrosis and pulmonary hypertension. 
Farmaceutski sastav prema bilo kojem zahtjevu 1, 4, 5 ili 6, naznačen time, da je upalna bolest pluća odabrana 1z skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
The reaction mixture is evaporated in vacuo, to remove MeOH then cooled in an ice bath and acidified with concentrated HCl. 
Reakcijsku smjesu se ispari u vakuumu da se odstrani MeOH, zatim se ohladi u ledenoj kupelji i zakiseli s koncentriranom HCI.
traditional draught beer devices or dispensing systems specialized for soft drinks, independent of the exact dispensing system. 
s tradicionalnim uređajima za pivo iz bačve ili sa sistemima za točenje posebno uređenim za bezalkoholna pića, neovisno o traženom sistemu za točenje.
The method of claim 16 which comprises cation exchange chromatography using a cation exchanger with a carboxylate functional group. 
Postupak prema zahtjevu 16, naznačen time, da obuhvaća kromatografiju kationske izmjene uz korištenje kationskog izmjenjivača s funkcionalnom karboksilatnom skupinom.
A process according to claim 1, wherein the dialysis fluid consists of acid, water, and sodium bicarbonate, and wherein the dialysis fluid further consists of substances that are required to reestablish ionic equilibrium of the blood. 
Postupak sukladno zahtjevu 1, naznačen time, da tekućina za dijalizu se sastoji od kiseline, vode 1 natrij bikarbonata, 1 pri čemu se tekućina za dijalizu nadalje sastoji od tvari koje su potrebne za ponovno uspostavljanje ionske ravnoteže krvi.
A herbicidal composition which comprises a herbicidally effective amount of a compound of formula I according to claim 1 in addition to formulation adjuvants. 
Herbicidni sastav, naznačen time, da sadrži herbicidno učinkovitu količinu spoja formule I uz dodatak formulacijskih pomoćnih sredstava.
The processes of the invention involve the use of sodium dodecyl sulfate (SDS), which is also known as sodium lauryl sulfate. 
Deterdžent Procesi iz izuma uključuju uporabu natrijevog dodecil sulfata (SDS), koji je također poznat kao natrijev lauril sulfat.